Erste Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Erste Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-51,200	Closed	-$480K	–	620
2025 Q4	$480K	Hold	51,200	–	–	﹤0.01%	504
2025 Q3	$358K	Hold	51,200	–	–	﹤0.01%	516
2025 Q2	$331K	Hold	51,200	–	–	﹤0.01%	700
2025 Q1	$413K	Hold	51,200	–	–	0.01%	440
2024 Q4	$659K	Hold	51,200	–	–	0.01%	417
2024 Q3	$725K	Hold	51,200	–	–	0.01%	405
2024 Q2	$708K	Hold	51,200	–	–	0.01%	397
2024 Q1	$808K	Hold	51,200	–	–	0.01%	388
2023 Q4	$767K	Hold	51,200	–	–	0.01%	395
2023 Q3	$635K	Hold	51,200	–	–	0.01%	384
2023 Q2	$628K	Hold	51,200	–	–	0.01%	398
2023 Q1	$653K	Buy	+51,200	New	+$1M	0.01%	403

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Erste Asset Management's DAWN Position: Q1 2026 in Review

Erste Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 51,200 shares — an estimated $480K sold.

Erste Asset Management first reported a position in DAWN in Q1 2023 and held it in 12 quarters. The position peaked at $808K in Q1 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Erste Asset Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Erste Asset Management sold 51,200 Day One Biopharmaceuticals shares in Q1 2026, an estimated $480K.
Erste Asset Management first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 12 quarters.
Erste Asset Management's Day One Biopharmaceuticals position peaked at $808K in Q1 2024.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Erste Asset Management's 13F filing for Q1 2026, filed 11 May 2026.